Cantuzumab mertansine

N/A

Report date: 2024/02/05 13:57:17

Base Information

Drug NameCantuzumab mertansine

Drug Alias Name美坎珠单抗C-242 DM1C-242 MayhuC242 maytansinoid conjugateMonoclonal antibody huC242-May conjugate +[13]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > SPP linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionApoptosis stimulantsMitosis inhibitorsMucin-1 inhibitors

TargetsMucin-1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesImmunogen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesImmunogen Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A